High-dose intravenous immunoglobulin may be an efficient treatment option for patients with late-onset high-grade immune effector cell-associated hematotoxicity refractory to standard therapies.

IF 8.2 1区医学 Q1 HEMATOLOGY Haematologica Pub Date : 2025-01-09 DOI:10.3324/haematol.2024.286714

Yousef Laham, Shimrit Ringelstein-Harlev, Daniel Kurnik, Riva Fineman, Dana Yehudai-Ofir, Lilach Bonstein, Noga Setter-Marco, Eyal Braun, Itai Ghersin, Tsila Zuckerman, Ofrat Beyar-Katz

引用次数: 0

Abstract

Not available.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

求助全文

约1分钟内获得全文去求助

来源期刊

Haematologica 医学-血液学

CiteScore

14.10

自引率

2.00%

发文量

349

审稿时长

3-6 weeks

期刊介绍： Haematologica is a journal that publishes articles within the broad field of hematology. It reports on novel findings in basic, clinical, and translational research. Scope: The scope of the journal includes reporting novel research results that: Have a significant impact on understanding normal hematology or the development of hematological diseases. Are likely to bring important changes to the diagnosis or treatment of hematological diseases.

期刊最新文献

High-dose intravenous immunoglobulin may be an efficient treatment option for patients with late-onset high-grade immune effector cell-associated hematotoxicity refractory to standard therapies. Interplay between circulating von Willebrand factor and neutrophils: implications for inflammation, neutrophil function, and von Willebrand factor clearance. Novel classification system and high-risk categories of pediatric acute myeloid leukemia. Purine metabolites regulate leukemic cell sensitivity toward cytarabine. Recipient sex and donor leukemic cell characteristics determine leukemogenesis in patient-derived models.